pubmed-article:21502923 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0015177 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0982327 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0162643 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:21502923 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
pubmed-article:21502923 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:21502923 | pubmed:dateCreated | 2011-4-19 | lld:pubmed |
pubmed-article:21502923 | pubmed:abstractText | To assess the safety and efficacy of 48 weeks of re-treatment with peginterferon ?-2a (40 kD) plus ribavirin in previously treated hepatitis C virus (HCV) genotype 1 patients. | lld:pubmed |
pubmed-article:21502923 | pubmed:language | eng | lld:pubmed |
pubmed-article:21502923 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21502923 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:21502923 | pubmed:month | May | lld:pubmed |
pubmed-article:21502923 | pubmed:issn | 1473-5687 | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:UrbanekPetrP | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:TietzAndreasA | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:HusaPetrP | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:MessingerDiet... | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:OltmanMarianM | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:IvanovskiLjub... | lld:pubmed |
pubmed-article:21502923 | pubmed:author | pubmed-author:RehákVratisla... | lld:pubmed |
pubmed-article:21502923 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:21502923 | pubmed:volume | 23 | lld:pubmed |
pubmed-article:21502923 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:21502923 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:21502923 | pubmed:pagination | 375-81 | lld:pubmed |
pubmed-article:21502923 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:meshHeading | pubmed-meshheading:21502923... | lld:pubmed |
pubmed-article:21502923 | pubmed:year | 2011 | lld:pubmed |
pubmed-article:21502923 | pubmed:articleTitle | Efficacy and safety of peginterferon ?-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. | lld:pubmed |
pubmed-article:21502923 | pubmed:affiliation | Department of Infectious Diseases, Faculty Hospital and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. phusa@fnbrno.cz | lld:pubmed |
pubmed-article:21502923 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:21502923 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:21502923 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:21502923 | pubmed:publicationType | Multicenter Study | lld:pubmed |